AzTrials
AzTrials

Open SurgeryPRECISENCT06725030

A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

An observational study of Open Surgery and Lymphedema, run by MMI (Medical Microinstruments, Inc.) at 8 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery. The primary endpoints are: Effectiveness- Rate of intraoperative anastomosis patency at first attempt. Read more about this study

Who is it for?
Ages 22 years and older
Conditions the study is for
Open Surgery, Lymphedema, Free Tissue Transfer
What is being tested?
Symani Surgical System
Type of treatment
Medical device
How many people
455 participants
Where
8 sitesUnited States
Study dates
22 Sep 2025to 1 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The patients selected for the PRECISE Study will be adults with a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities.

Pre Operative Inclusion Criteria:

  1. At least 22 years of age
  2. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure
  3. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free-flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities
  4. Investigator deems the candidate acceptable for free flap transfer surgery and/or lymphovenous anastomosis surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)

Cohort Specific Pre- Operative Inclusion Criteria:

Free Tissue Transfer Surgery: N/A

Lymphovenous Anastomosis Surgery

  1. Swelling of one limb that is not completely reversed by elevation or compression
  2. Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system
  3. At least one of the following positive quantitative measurements:
  4. Volumetry differential between affected limb and contralateral limb must be at least 10% of the other
  5. Bioimpedance (L-Dex) differential, if feasible, between affected limb and contralateral limb of at least 10 units
  6. Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines, for at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen
  7. Willingness to comply with recommended regimen of self-care, with consistent use of appropriately sized compression garments from screening through the entire study duration (through the 3-month follow-up visit).

Pre-Operative Exclusion Criteria:

  1. Patients who are incapable and/or unwilling to provide informed consent
  2. Active systemic infection under treatment with intravenous antibiotics
  3. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion
  4. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
  5. Patients with implanted pacemaker
  6. Planned vein graft
  7. Currently receiving chemotherapy or radiation therapy
  8. History of chronic kidney disease
  9. History of chronic liver disease
  10. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes
  11. Patients belonging to vulnerable populations, such as pregnant women, or ineligible to participate for other reasons in the judgement of the investigator

Cohort Specific Pre-Operative Exclusion Criteria:

Free Tissue Transplant Surgery:

  1. Patients with buried flaps
  2. Multiple flaps planned for the procedure

Lymphovenous Anastomosis Surgery:

  1. Patients > 75 years of age
  2. Patients with prior lymphatic reconstruction surgery
  3. Patients with venous edema (arising from increased capillary filtration)
  4. Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure
  5. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema
  6. Current infection in the affected limb
  7. Patients who experience more than one episode of cellulitis in a six month period over the past two years
  8. Current evidence or a history of malignancy within the past 6 months (if the participant has undergone cancer treatment, this must have been completed > 6 months prior to enrollment)
  9. Known iodine sensitivity
  10. Patient's lymphatic disease is due to lipedema
  11. Patients with bilateral lymphedema or lymphedema in multiple anatomical locations

Intra Operative Exclusion Criteria:

  1. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest
  2. The patient does not have at least one robotic stitch attempted during the index procedure

Trial locations and contacts

8 sites in 1 country. Contact the study team or a site near you to ask about taking part.

8 sites in 1 country

United States8 sites, 8 recruiting
  • Cedars Sinai Medical Center

    Beverly Hills, California, 90048

    Laura Sarmiento, Laura.Sarmiento@cshs.org

    Curtis Cetrulo

    Recruiting
  • Erie County Medical Center

    Buffalo, New York, 14215

    Sonja Williams, swilliam8@ecmc.edu

    Mark Falco

    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Beverly Doyle, plasticsurgeryresearch@ccf.org

    Graham Schwarz

    Recruiting
  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601

    Samuel Belony, samuel.belony@hmhn.org

    Richard Winters

    Recruiting
  • Yale New Haven Hospital

    New Haven, Connecticut, 06511

    Kyra Jersey, kyra.jersey@yale.edu

    Luccie Wo

    Recruiting
  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029

    Emily Svendsen, Emily.Svendsen@mountsinai.org

    Alice Yao

    Recruiting
  • HCA Healthcare Trident Hospital

    North Charleston, South Carolina, 29406

    Vera Markovic, vera.markovic@hcahealthcare.com

    Joshua Hornig

    Recruiting
  • Tampa General Hospital

    Tampa, Florida, 33606

    Chloe Grabowski, cchapin@tgh.org

    Nicholas Panetta

    Recruiting

Other trials in United States

About this study

Official title: PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.

The primary endpoints are:

Read more
  • Effectiveness- Rate of intraoperative anastomosis patency at first attempt.
  • Safety- Freedom from device-related adverse events.

Participants will receive treatment as standard of care and be asked to:

  • Allow the researchers to access and use their information.
  • If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.
  • Participants will be asked to comply with the follow-up visits and complete all study procedures/questionnaires as outlined in the protocol.
Being tested
Symani Surgical System
Medical subject headings
Lymphedema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Symani Surgical SystemDevice

    The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.

Study groups in NCT06725030
Study groupRoleWhat they receive
Free Tissue Transfer SurgeryNot described
Receives: Device: Symani Surgical System
Lymphovenous Anastomosis SurgeryNot described
Receives: Device: Symani Surgical System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee

    All adverse events will be evaluated from the start of the index procedure through 30-days post index procedure. Adverse events will be reviewed by a Clinical Events Committee (CEC) to determine probable or causal relationships with the device. All device-related serious adverse events will be summarized descriptively.

    Measured: From participants index procedure through 30-days post index procedure.

  2. Intraoperative anastomosis patency at first attempt.

    Intraoperative anastomosis patency will be measured for each robotic anastomosis per standard of care and will be evaluated after the first attempt of the anastomosis during the index procedure.

    Measured: The duration of the participants index procedure.

Secondary outcomes (5)
  1. Intraoperative anastomosis patency prior to closure.

    Intraoperative anastomosis patency prior to closure will be measured for each robotic anastomosis per standard of care and will be evaluated prior to closure of the procedure site during the index procedure.

    Measured: The duration of participants index procedure.

  2. Anastomosis suturing time (including robotic time and manual time).

    Anastomosis suturing time of the index procedure will be collected for each participant and summarized. Robotic anastomosis time and manual anastomosis time will be recorded for each anastomosis. For each anastomosis within an operation, the total suture time (robotic plus manual) will be derived as total robotic anastomosis time plus total manual anastomosis time.

    Measured: The duration of participants index procedure.

  3. Number of robotic and manual stitches per anastomosis.

    The number of robotic stitches placed and the number of manual stitches placed per anastomosis in the index procedure will be collected for each anastomosis and summarized. For each anastomosis within an operation, the total stitches placed (robotic plus manual) will be derived as total robotic stitches placed plus total manual stitches.

    Measured: The duration of participants index procedure.

  4. Procedure time.

    Procedure time of the index procedure will be collected for each participant and summarized. The incision start time and closure end time will be recorded. The procedural time will be derived from incision time subtracted from closure time.

    Measured: The duration of participants index procedure.

  5. Technical Success.

    Technical success is defined as freedom from device malfunction resulting in unplanned conventional suturing. Device malfunctions and the associated outcome will be collected. This endpoint will be evaluated throughout the index procedure.

    Measured: The duration of participants index procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2024
  2. Study start22 Sep 2025
  3. Primary completion1 Sep 2027 (estimated)
  4. Study completion1 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
455 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06725030
Sponsor's protocol ID
CDC-00136
Acronym
PRECISE
Status last verified
Nov 2026
First submitted
5 Dec 2024
Last updated
4 Nov 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Open Surgery and Lymphedema, run by MMI (Medical Microinstruments, Inc.) at 8 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Operations (8336646276 ext. 5, clinical.ops@mmimicro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee (time frame: From participants index procedure through 30-days post index procedure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in